INSILICO (03696.HK): considering participation in RMB 1.01 billion investment fund focusing on biopharma

NewTimeSpace News: On 18 August 2026, InSilico Medicine (stock code: 03696) announced in a voluntary announcement that it is considering participating in the proposed establishment of an investment fund tentatively named Insilico SPDB Value Partners (Shanghai) Private Equity Investment Fund Partnership (Limited Partnership). As part of the implementation structure, the Company proposes to contribute RMB 3 million through its wholly-owned subsidiary InSilico Medicine (Shanghai) Investment Co., Ltd. to jointly establish a joint venture with Shanghai Pudong Construction Co., Ltd. (600284.SH) and Shanghai Pudong Development (Group) Co., Ltd. (the controlling shareholder of Pudong Construction), with the Company's contribution expected to represent 60% of the joint venture's registered capital of RMB 5 million; upon its establishment, the joint venture is expected to become an indirect non-wholly-owned subsidiary of the Company, with its financial results expected to be consolidated into the Group's accounts.

According to the announcement, following the establishment of the joint venture, the Company proposes to contribute an aggregate of RMB 302.5 million through its wholly-owned subsidiary InSilico Medicine Technology (Shanghai) Co., Ltd. and the joint venture, to jointly establish the fund with Value Partners Equity Investment Management (Shenzhen) Co., Ltd. (a wholly-owned subsidiary of Value Partners Group Limited (00806.HK)), Pudong Construction and other potential investors. The fund is proposed to be established in China as a limited partnership, focusing primarily on investments in biopharmaceuticals and other related sectors, with a target fund size of approximately RMB 1.01 billion.

The announcement states that the Board considers the potential transactions to be in line with the Group's strategic development direction and helpful in capturing growth opportunities arising from the continued development and innovation in biopharmaceuticals and life sciences; as of the date of the announcement, no definitive agreements have been entered into for the potential transactions, which may not proceed, and if definitive agreements are entered into, they are expected to constitute discloseable transactions under Chapter 14 of the Listing Rules.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.